FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979697044> ?p ?o ?g. }

• W2979697044 endingPage "vi118" @default.
• W2979697044 startingPage "vi118" @default.
• W2979697044 abstract "Abstract Background Fluoropyrimidine (Fp) is one of the key drugs of chemotherapy in unresectable colorectal cancer (CRC), and usually used not only in first-line but also in second-line as beyond progression. The efficacy in combination of irinotecan, oxaliplatin and bevacizumab (BEV) with various types of Fp such as S-1, capecitabine and 5-FU were reportedly equivalent. However, clinical impacts of Fp switching between first- and second-line treatment are not well known. Here, we investigated the efficacy of Fp switching in sequential treatment of chemotherapy in unresectable CRC. Method We retrospectively reviewed the medical records of patients with unresectable CRC who had received doublet with BEV both in first- and second-line at our hospital between January 2012 and December 2016. Patients were divided into two groups: patients who received Fp switching and no switching through the sequential treatment. Results A total of 28 patients were analyzed. Seven patients received Fp switching and 21 patients received no switching: the median age was 43/65 years, male was 86/48%, performance status of 0 was 100/86%, RAS wild type was 57/43%, primary site of right side was 43/52% and more than 2 metastases was 43/62% respectively. Details of Fp switching were: changes from 5-FU to cape in one (14%), from cape to 5-FU in 4 (57%), from S-1 to cape in 2 (28%). The median progression-free survival of Fp switching and no switching was: 10.5 and 8.3 months (m) in first-line (p = 0.881), 5.1/4.8 m in second-line (p = 0.692), and 18.9/19.1 m in first + second-line (p = 0.537), respectively. Overall survival was 23.2/24.3 m (p = 0.537), respectively. Objective response rate was 67/55% (p = 0.404) in first-line, and 0/5% (p = 0.760) in second-line, respectively. Conclusions There were no significant differences in the efficacy of Fp switching in this study." @default.
• W2979697044 created "2019-10-18" @default.
• W2979697044 creator A5000250722 @default.
• W2979697044 creator A5000810330 @default.
• W2979697044 creator A5005964437 @default.
• W2979697044 creator A5007771941 @default.
• W2979697044 creator A5010886312 @default.
• W2979697044 creator A5034496993 @default.
• W2979697044 creator A5038654104 @default.
• W2979697044 creator A5045059146 @default.
• W2979697044 creator A5048908270 @default.
• W2979697044 creator A5054899877 @default.
• W2979697044 creator A5057728015 @default.
• W2979697044 creator A5066413780 @default.
• W2979697044 creator A5077827101 @default.
• W2979697044 creator A5083128998 @default.
• W2979697044 creator A5089649906 @default.
• W2979697044 date "2019-10-01" @default.
• W2979697044 modified "2023-09-28" @default.
• W2979697044 title "Impact of fluoropyrimidine switching in sequential treatment of first- and second-line n unresectable colorectal cancer" @default.
• W2979697044 doi "https://doi.org/10.1093/annonc/mdz343.001" @default.
• W2979697044 hasPublicationYear "2019" @default.
• W2979697044 type Work @default.
• W2979697044 sameAs 2979697044 @default.
• W2979697044 citedByCount "0" @default.
• W2979697044 crossrefType "journal-article" @default.
• W2979697044 hasAuthorship W2979697044A5000250722 @default.
• W2979697044 hasAuthorship W2979697044A5000810330 @default.
• W2979697044 hasAuthorship W2979697044A5005964437 @default.
• W2979697044 hasAuthorship W2979697044A5007771941 @default.
• W2979697044 hasAuthorship W2979697044A5010886312 @default.
• W2979697044 hasAuthorship W2979697044A5034496993 @default.
• W2979697044 hasAuthorship W2979697044A5038654104 @default.
• W2979697044 hasAuthorship W2979697044A5045059146 @default.
• W2979697044 hasAuthorship W2979697044A5048908270 @default.
• W2979697044 hasAuthorship W2979697044A5054899877 @default.
• W2979697044 hasAuthorship W2979697044A5057728015 @default.
• W2979697044 hasAuthorship W2979697044A5066413780 @default.
• W2979697044 hasAuthorship W2979697044A5077827101 @default.
• W2979697044 hasAuthorship W2979697044A5083128998 @default.
• W2979697044 hasAuthorship W2979697044A5089649906 @default.
• W2979697044 hasBestOaLocation W29796970441 @default.
• W2979697044 hasConcept C121608353 @default.
• W2979697044 hasConcept C126322002 @default.
• W2979697044 hasConcept C143998085 @default.
• W2979697044 hasConcept C2776694085 @default.
• W2979697044 hasConcept C2777802072 @default.
• W2979697044 hasConcept C2777909004 @default.
• W2979697044 hasConcept C2778336483 @default.
• W2979697044 hasConcept C2780259306 @default.
• W2979697044 hasConcept C2780456651 @default.
• W2979697044 hasConcept C2780739268 @default.
• W2979697044 hasConcept C2780962732 @default.
• W2979697044 hasConcept C526805850 @default.
• W2979697044 hasConcept C71924100 @default.
• W2979697044 hasConceptScore W2979697044C121608353 @default.
• W2979697044 hasConceptScore W2979697044C126322002 @default.
• W2979697044 hasConceptScore W2979697044C143998085 @default.
• W2979697044 hasConceptScore W2979697044C2776694085 @default.
• W2979697044 hasConceptScore W2979697044C2777802072 @default.
• W2979697044 hasConceptScore W2979697044C2777909004 @default.
• W2979697044 hasConceptScore W2979697044C2778336483 @default.
• W2979697044 hasConceptScore W2979697044C2780259306 @default.
• W2979697044 hasConceptScore W2979697044C2780456651 @default.
• W2979697044 hasConceptScore W2979697044C2780739268 @default.
• W2979697044 hasConceptScore W2979697044C2780962732 @default.
• W2979697044 hasConceptScore W2979697044C526805850 @default.
• W2979697044 hasConceptScore W2979697044C71924100 @default.
• W2979697044 hasLocation W29796970441 @default.
• W2979697044 hasOpenAccess W2979697044 @default.
• W2979697044 hasPrimaryLocation W29796970441 @default.
• W2979697044 hasVolume "30" @default.
• W2979697044 isParatext "false" @default.
• W2979697044 isRetracted "false" @default.
• W2979697044 magId "2979697044" @default.
• W2979697044 workType "article" @default.